• Immunovant posted a fiscal Q4 net loss of $147.86 million, or $0.73 per share, widening from $106.45 million, or $0.64 per share, a year earlier.
• Research and development expense climbed 51.91% to $142.29 million, while general and administrative expense fell 14.41% to $17.27 million.
• Cash and cash equivalents totaled $902.11 million as of March 31, 2026.
• Development of batoclimab was discontinued across all indications following two Phase 3 thyroid eye disease studies that missed the primary endpoint; the company is refocusing on IMVT-1402.
• IMVT-1402 showed Week 16 response rates of 72.7% ACR20 and 54.5% ACR50 in an open-label difficult-to-treat rheumatoid arthritis trial, with additional updates expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.